StockNews.com assumed coverage on shares of Aeglea BioTherapeutics (NASDAQ:AGLE – Get Rating) in a report published on Monday. The firm issued a hold rating on the biotechnology company's stock.

AGLE has been the subject of a number of other reports. Wells Fargo & Company upgraded shares of Aeglea BioTherapeutics from an equal weight rating to an overweight rating and boosted their price objective for the stock from $1.50 to $2.00 in a report on Friday, October 28th. Piper Sandler boosted their price target on Aeglea BioTherapeutics to $1.50 in a research note on Tuesday, November 1st. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of Moderate Buy and an average target price of $1.88.

Aeglea BioTherapeutics Trading Down 5.5 %

Aeglea BioTherapeutics stock opened at $0.48 on Monday. Aeglea BioTherapeutics has a 12 month low of $0.34 and a 12 month high of $4.54. The company has a market capitalization of $29.65 million, a price-to-earnings ratio of -0.42 and a beta of 1.66. The business's fifty day simple moving average is $0.54 and its two-hundred day simple moving average is $0.60.

Institutional Investors Weigh In On Aeglea BioTherapeutics

Large investors have recently added to or reduced their stakes in the stock. Two Sigma Advisers LP lifted its holdings in shares of Aeglea BioTherapeutics by 76.9% during the 3rd quarter. Two Sigma Advisers LP now owns 409,900 shares of the biotechnology company's stock valued at $216,000 after buying an additional 178,200 shares during the period. Ghost Tree Capital LLC boosted its position in Aeglea BioTherapeutics by 8.1% in the third quarter. Ghost Tree Capital LLC now owns 1,000,000 shares of the biotechnology company's stock worth $526,000 after purchasing an additional 75,000 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Aeglea BioTherapeutics by 5.6% during the 2nd quarter. Goldman Sachs Group Inc. now owns 1,187,293 shares of the biotechnology company's stock valued at $600,000 after purchasing an additional 62,504 shares during the period. Nantahala Capital Management LLC increased its position in shares of Aeglea BioTherapeutics by 21.1% during the 2nd quarter. Nantahala Capital Management LLC now owns 3,877,311 shares of the biotechnology company's stock valued at $1,958,000 after purchasing an additional 676,718 shares during the last quarter. Finally, Bain Capital Life Sciences Investors LLC lifted its stake in shares of Aeglea BioTherapeutics by 87.8% in the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 5,347,689 shares of the biotechnology company's stock worth $2,701,000 after purchasing an additional 2,500,000 shares during the period. Institutional investors own 78.01% of the company's stock.

About Aeglea BioTherapeutics

(Get Rating)

Aeglea Biotherapeutics, Inc is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency.

Read More

• Get a free copy of the StockNews.com research report on Aeglea BioTherapeutics (AGLE)
• Why Gold Can Be A Glistening Addition To Your Portfolio Right Now
• SoFi Technologies Smashes Earnings but Beware the Fed Decision
• Buying The Dip In Colgate-Palmolive
• Mullen Automotive On Hiring Spree, What Could That Mean?
• InterDigital Raises Its Earnings Guidance

Receive News & Ratings for Aeglea BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.